Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAS1440 + ATRA
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TAS1440 + ATRA is an investigational combination therapy being developed by Taiho Oncology for the treatment of relapsed or refractory acute myeloid leukemia (AML). TAS1440 is a small molecule inhibitor of lysine-specific demethylase 1 (LSD1), an epigenetic enzyme that plays a critical role in maintaining the undifferentiated state of AML blasts. All-trans retinoic acid (ATRA) is a vitamin A derivative that induces differentiation in myeloid cells. Preclinical studies suggest that LSD1 inhibition sensitizes non-promyelocytic AML cells to ATRA-induced differentiation, potentially overcoming the resistance typically seen in these subtypes. The combination is currently being evaluated in a Phase 1 clinical trial (NCT04282668) to assess safety, pharmacokinetics, and preliminary efficacy.
- Brand names
- Vesanoid
- Other names
- TAS1440 + all-trans retinoic acidTAS1440 + tretinoin
02
Targets
KDM1A (LSD1)RARA (Retinoic acid receptor alpha)
Beyond the preview
Go deeper on TAS1440 + ATRA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAS1440 + ATRA.